Tags

Type your tag names separated by a space and hit enter

Genetic alterations of differentiated thyroid carcinoma in iodine-rich and iodine-deficient countries.
Cancer Med. 2016 08; 5(8):1883-9.CM

Abstract

BRAF V600E mutation, RET rearrangements, and RAS mutations are the common genetic alterations in differentiated thyroid carcinomas derived from follicular thyroid cells. However, the relationship between these alterations and iodine intake is still controversial. To clarify the influence of iodine intake on the occurrence of differentiated thyroid carcinomas, we performed molecular analyses for two differentiated carcinomas, papillary thyroid carcinomas (PTCs) and follicular thyroid carcinomas (FTCs), from an iodine-rich country (Japan) and an iodine-deficient country (Vietnam). We examined 120 PTCs (67 Japanese and 53 Vietnamese) and 74 FTCs (51 Japanese and 23 Vietnamese). We carried out allele-specific polymerase chain reaction (AS-PCR) for BRAF V600E, PCR and direct sequencing for RAS mutations (codon 12, 13, and 61 in NRAS, HRAS, and KRAS), and RT-PCR for RET/PTC1 and RET/PTC3. BRAF V600E was present in 55/67 (82.1%) Japanese PTCs and 44/53 (83%) Vietnamese PTCs. RET/PTC1 was identified in only one PTC from each country, and no samples had RET/PTC3. NRAS mutation was found in 17/51 (33.3%) Japanese FTCs and 4/23 (17.4%) Vietnamese FTCs. NRAS mutation was cited in codon 61 (20 cases) and codon 12 (one case). None of FTCs had KRAS or HRAS mutations. There were no significant differences in the prevalence of BRAF V600E, RET/PTC, or RAS mutations between the two countries. Our study showed no differences in genetic alterations of thyroid cancers from iodine-rich and iodine-deficient countries, possibly suggesting that iodine intake might not affect the genetic alterations of differentiated thyroid cancer.

Authors+Show Affiliations

Department of Pathology, University of Yamanashi, Yamanashi, Japan. Department of Pathology, Cho Ray Hospital, Ho Chi Minh, Vietnam.Department of Pathology, University of Yamanashi, Yamanashi, Japan.Department of Pathology, University of Yamanashi, Yamanashi, Japan.Department of Pathology, University of Yamanashi, Yamanashi, Japan.Department of Pathology, University of Yamanashi, Yamanashi, Japan.Department of Pathology, University of Yamanashi, Yamanashi, Japan.Department of Pathology, University of Yamanashi, Yamanashi, Japan.Department of Pathology, University of Yamanashi, Yamanashi, Japan.Department of Pathology, Kuma Hospital, Kobe, Japan.Department of Pathology, Cho Ray Hospital, Ho Chi Minh, Vietnam.Department of Pathology, University of Yamanashi, Yamanashi, Japan.

Pub Type(s)

Journal Article
Multicenter Study

Language

eng

PubMed ID

27264674

Citation

Vuong, Huy Gia, et al. "Genetic Alterations of Differentiated Thyroid Carcinoma in Iodine-rich and Iodine-deficient Countries." Cancer Medicine, vol. 5, no. 8, 2016, pp. 1883-9.
Vuong HG, Kondo T, Oishi N, et al. Genetic alterations of differentiated thyroid carcinoma in iodine-rich and iodine-deficient countries. Cancer Med. 2016;5(8):1883-9.
Vuong, H. G., Kondo, T., Oishi, N., Nakazawa, T., Mochizuki, K., Inoue, T., Tahara, I., Kasai, K., Hirokawa, M., Tran, T. M., & Katoh, R. (2016). Genetic alterations of differentiated thyroid carcinoma in iodine-rich and iodine-deficient countries. Cancer Medicine, 5(8), 1883-9. https://doi.org/10.1002/cam4.781
Vuong HG, et al. Genetic Alterations of Differentiated Thyroid Carcinoma in Iodine-rich and Iodine-deficient Countries. Cancer Med. 2016;5(8):1883-9. PubMed PMID: 27264674.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Genetic alterations of differentiated thyroid carcinoma in iodine-rich and iodine-deficient countries. AU - Vuong,Huy Gia, AU - Kondo,Tetsuo, AU - Oishi,Naoki, AU - Nakazawa,Tadao, AU - Mochizuki,Kunio, AU - Inoue,Tomohiro, AU - Tahara,Ippei, AU - Kasai,Kazunari, AU - Hirokawa,Mitsuyoshi, AU - Tran,Thong Minh, AU - Katoh,Ryohei, Y1 - 2016/06/05/ PY - 2016/02/19/received PY - 2016/05/01/revised PY - 2016/05/02/accepted PY - 2016/6/7/entrez PY - 2016/6/7/pubmed PY - 2017/11/8/medline KW - BRAF KW - RAS KW - RET/PTC KW - follicular KW - iodine intake KW - papillary KW - thyroid cancer SP - 1883 EP - 9 JF - Cancer medicine JO - Cancer Med VL - 5 IS - 8 N2 - BRAF V600E mutation, RET rearrangements, and RAS mutations are the common genetic alterations in differentiated thyroid carcinomas derived from follicular thyroid cells. However, the relationship between these alterations and iodine intake is still controversial. To clarify the influence of iodine intake on the occurrence of differentiated thyroid carcinomas, we performed molecular analyses for two differentiated carcinomas, papillary thyroid carcinomas (PTCs) and follicular thyroid carcinomas (FTCs), from an iodine-rich country (Japan) and an iodine-deficient country (Vietnam). We examined 120 PTCs (67 Japanese and 53 Vietnamese) and 74 FTCs (51 Japanese and 23 Vietnamese). We carried out allele-specific polymerase chain reaction (AS-PCR) for BRAF V600E, PCR and direct sequencing for RAS mutations (codon 12, 13, and 61 in NRAS, HRAS, and KRAS), and RT-PCR for RET/PTC1 and RET/PTC3. BRAF V600E was present in 55/67 (82.1%) Japanese PTCs and 44/53 (83%) Vietnamese PTCs. RET/PTC1 was identified in only one PTC from each country, and no samples had RET/PTC3. NRAS mutation was found in 17/51 (33.3%) Japanese FTCs and 4/23 (17.4%) Vietnamese FTCs. NRAS mutation was cited in codon 61 (20 cases) and codon 12 (one case). None of FTCs had KRAS or HRAS mutations. There were no significant differences in the prevalence of BRAF V600E, RET/PTC, or RAS mutations between the two countries. Our study showed no differences in genetic alterations of thyroid cancers from iodine-rich and iodine-deficient countries, possibly suggesting that iodine intake might not affect the genetic alterations of differentiated thyroid cancer. SN - 2045-7634 UR - https://www.unboundmedicine.com/medline/citation/27264674/Genetic_alterations_of_differentiated_thyroid_carcinoma_in_iodine_rich_and_iodine_deficient_countries_ L2 - https://doi.org/10.1002/cam4.781 DB - PRIME DP - Unbound Medicine ER -